A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumors

NCT06437522 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

46

Enrollment

INDUSTRY

Sponsor class

Conditions

Head and Neck Squamous Cell Carcinoma

Interventions

DRUG: BL-B01D1
DRUG: PD-1 monoclonal antibody

Sponsor

Sichuan Baili Pharmaceutical Co., Ltd.

Collaborators

[object Object]